AllCells’ Post

Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along | American Society of Clinical Oncology Educational Book (ascopubs.org)

"Non-invasive tests may actually hold more predictive value than imaging tests, which makes sense because they can detect disease at a much lower level...perhaps this is an opportunity to improve the way we define remission." Mark Roschewski discusses the findings and implications from his recent study presented at #ash23 that compared the performance of PhasED-Seq ctDNA vs. PET/CT scans for response assessment after frontline therapy for aggressive #DLBCL. These findings require us to rethink how we best measure response in lymphoma - and this is particularly critical for clinical trials. When used in conjunction with standard PET/CT imaging, PhasED-Seq's ultra-sensitive ctDNA platform may be a more accurate measure of response, and thereby, a more confident indicator of therapeutic efficacy for drug development and approvals. Watch the full video here: https://lnkd.in/dqJvbfw9 #mrd #ctdna #lymphoma #clinicaltrials

🌍 On Lung Cancer Awareness Month, let's reflect on the importance of raising awareness and supporting research in this area. Lung cancer remains one of the leading causes of death worldwide. 🔬 HAWK Biosystems is committed to research and exploring more precise ways to approach immunotherapy, with the potential to significantly improve responses and survival. 🌟 These advancements aim not only to enhance the treatment landscape but also to optimize investments for more effective outcomes. 🔍 Current research could change the game in the fight against lung cancer, offering hope to those battling this disease. 🏥 Very soon our technology will contribute to this advancement in lung cancer treatment. Read more: https://lnkd.in/eJpGCmz4 Together, we move towards a future with better responses to lung cancer. Join the fight!

𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗢𝗿𝗴𝗮𝗻𝗶𝘇𝗲𝗿: 𝗜𝘀 𝘁𝗵𝗲𝗿𝗲 𝗮 𝗱𝗼𝗰𝘁𝗼𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗵𝗼𝘂𝘀𝗲? 𝘠𝘰𝘶𝘳 𝘔𝘋 𝘧𝘳𝘪𝘦𝘯𝘥: 𝘠𝘦𝘴, 𝘐'𝘮 𝘢𝘯 𝘦𝘮𝘦𝘳𝘨𝘦𝘯𝘤𝘺 𝘱𝘩𝘺𝘴𝘪𝘤𝘪𝘢𝘯. 𝘏𝘰𝘸 𝘤𝘢𝘯 𝘐 𝘩𝘦𝘭𝘱? 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗢𝗿𝗴𝗮𝗻𝗶𝘇𝗲𝗿: 𝗠𝘆 𝗮𝗽𝗼𝗹𝗼𝗴𝗶𝗲𝘀. 𝗟𝗲𝘁 𝗺𝗲 𝗯𝗲 𝗰𝗹𝗲𝗮𝗿𝗲𝗿. 𝗔𝗿𝗲 𝘁𝗵𝗲𝗿𝗲 𝗮𝗻𝘆 #VariantClassification 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗵𝗼𝘂𝘀𝗲? 𝗪𝗲 𝗵𝗮𝘃𝗲 𝗮𝗻 𝘂𝗿𝗴𝗲𝗻𝘁 #ClinicalGenetics 𝘀𝗶𝘁𝘂𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗱𝗲𝗮𝗹 𝘄𝗶𝘁𝗵. 𝘠𝘰𝘶 𝘢𝘯𝘥 𝘺𝘰𝘶𝘳 𝘤𝘰𝘭𝘭𝘦𝘢𝘨𝘶𝘦𝘴 𝘴𝘵𝘳𝘪𝘥𝘪𝘯𝘨 𝘧𝘰𝘳𝘵𝘩 𝘸𝘪𝘵𝘩 𝘥𝘦𝘵𝘦𝘳𝘮𝘪𝘯𝘢𝘵𝘪𝘰𝘯: 𝘏𝘰𝘸 𝘤𝘢𝘯 𝘸𝘦 𝘩𝘦𝘭𝘱? 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗢𝗿𝗴𝗮𝗻𝗶𝘇𝗲𝗿: *𝘄𝗲𝗲𝗽𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗴𝗿𝗮𝘁𝗶𝘁𝘂𝗱𝗲* 𝗙𝗼𝗹𝗹𝗼𝘄 𝗺𝗲 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀. 𝗜𝘁'𝘀 𝘁𝗶𝗺𝗲 𝘁𝗼 𝘂𝗽𝗱𝗮𝘁𝗲 𝘁𝗵𝗲 𝘃𝗮𝗿𝗶𝗮𝗻𝘁 𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀 𝗮𝗻𝗱 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀. This is it. This is your moment. #VariantClassification 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 assemble! See: https://lnkd.in/g-zfAmwA Corporate Workshop: ACMG/AMP/CAP/ClinGen DRAFT Standards for Sequence Variant Classification v4.0 Join members of the ClinGen community at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo in Salt Lake City. Wednesday, November 15, 2023 I 4:00 PM – 4:50 PM MST Steven Harrison, PhD FACMG & Heidi Rehm It is FREE to attend Corporate Workshop Day; however, this year registration is REQUIRED. If you are already registered for the AMP Annual Meeting – as an attendee or booth staff – please pick up your badge prior to attending any Corporate Workshops. If you are not registered for the AMP Annual Meeting, you will need to register for Corporate Workshop Day. Registration is FREE, you will just need to complete the registration form linked below and pick-up your badge from the Main registration area. Association for Molecular Pathology (AMP), ClinGen Resource, ACMG - American College of Medical Genetics and Genomics, College of American Pathologists (CAP) #ClinicalGenetics #Genetics #Genomics #PrecisionMedicine #RareDisease #FDA #LDT #LDTs #CAP #CLIA #PrecisionOncology #GCchat #ELEVATEGENETICS

Going to AMP? Come hear about the upcoming version of variant classification guidelines we have been working on!

PUBLICATION: Here’s a great paper on the Journal of Clinical #Oncology (with CDI Labs CSO, Tyler Hulett) highlighting how our #HuProt™ protein #microarray demonstrated the potential to predict and mitigate severe immune-related adverse events (#irAEs) that may cause patients to withdraw from their treatment. With HuProt assays, we’re providing a unique capability that could help clinicians optimize #immunotherapy delivery, enhance patient selection, and prevent irAEs that may lead to treatment suppression. Studies like this exemplify the remarkable potential of #antibody #seromics in personalized immunotherapy. https://lnkd.in/dDJirM-t

Come learn about the latest draft of the sequence variant classification guidelines!

Vivli Researcher Spotlight: 🔦 Check out our newest update, with researcher Dr. Ashley Hopkins on using Vivli to access #individualpatientdata and making an impact in #cancertreatment: 👉 https://lnkd.in/gPNFVpRi

Schedule a meeting with the experts from Discovery Life Sciences at #ASCO24

Check out my interview with "The Onc Doc": Sanjay Juneja, M.D. on his podcast "Target Cancer." We discuss how the SAGE Oncotest can guide you and your oncologist to identify the best treatment for your very unique cancer.